Interestingly, thiopurines, drugs often used in the treatment of inflammatory bowel disease (IBD), have been shown to prevent activation of Rac1, resulting in a relative shift in the Rac1/RhoA balance towards RhoA (Sander et al., 1999). This evidence concerns the gene RAC1 and inflammatory bowel disease.